Early Ibuprofen Not Beneficial for Preemies With Patent Ductus Arteriosus

25 Jan 2024
www.drugs.com
Clinical ResultClinical Study
THURSDAY, Jan. 25, 2024 -- For extremely preterm infants, the risk for death or moderate or severe bronchopulmonary dysplasia is not significantly lower among those receiving early treatment for patent ductus arteriosus (PDA) with ibuprofen versus placebo, according to a study published in the Jan. 25 issue of the New England Journal of Medicine.
Samir Gupta, M.D., from Sidra Medicine in Doha, Qatar, and colleagues conducted a multicenter, randomized, double-blind, placebo-controlled trial assessing early ibuprofen treatment (≤72 hours after birth) for a large PDA (diameter ≥1.5 mm with pulsatile flow) in extremely preterm infants. Overall, 326 and 327 infants were assigned to receive ibuprofen and placebo, respectively; 324 and 322 had data available for outcome analyses. A composite of death or moderate or severe bronchopulmonary dysplasia evaluated at 36 weeks of postmenstrual age was the primary outcome.
The researchers found that a primary outcome event occurred in 69.2 and 63.5 percent of infants in the ibuprofen and placebo groups, respectively (adjusted risk ratio, 1.09; 95 percent confidence interval [CI], 0.98 to 1.20; P = 0.10); 13.6 and 10.3 percent of infants, respectively, died (adjusted risk ratio, 1.32; 95 percent confidence interval, 0.92 to 1.90). Moderate or severe bronchopulmonary dysplasia occurred in 64.2 and 59.3 percent of the ibuprofen and placebo groups, respectively, among the infants who survived to 36 weeks of postmenstrual age (adjusted risk ratio, 1.09; 95 percent confidence interval, 0.96 to 1.23).
"Our results are broadly consistent with those of other studies of early targeted treatment of PDA with ibuprofen that have not shown a convincing benefit with respect to clinical outcomes," the authors write.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
-
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.